AACR: Neoadjuvant, Adjuvant Durvalumab Beneficial for NSCLC

MONDAY, May 1, 2023 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant and adjuvant durvalumab offers benefits in terms of pathologic complete response and event-free survival (EFS), according to a study presented at the...